Cold Kits


• Hepatobiliary function studies
• Evaluation of bile flow, and diagnosis of extrahepatic biliary obstruction, malfunctioning gall-bladder, gall-bladder inflammation, biliary duct artresia, biliary cysts or similar pathologic alterations of the biliary duct.



The Tc-99m labelled compound can be used for static (planar or tomographic) renal imaging:

  • Kidney scintigraphy, static imaging of kidney location
  • Determination of functional kidney weight
  • Determine the relative function (%) of the right and left kidneys


The Tc-99m labelled compound can be used for:
After labeling with sterile 99mTc-pertechnetate solution, it is indicated for:

  • Determination of glomerular filtration (GFR)
  • Visualization of the kidney by sequential scintigraphy
  • Renal perfusion studies
  • Urinary tract studies
  • Renal artery stenosis
  • Estimation of transplanted kidney function
  • Vesico-urethral reflux
  • Visualization of brain lesions (tumor, bleeding)
  • Inhalation pulmonary scintigraphy (using a suitable nebulizer)




Regional cerebral blood flow (stroke, carotid artery occlusion, transient ischaemic attack, migraine, tumours of the brain, dementia differential diagnosis).

  • HM-PAO kit can be applied for detection, localisation of cortical areas with decreased perfusion, and to estimate the extent of the damage.
  • Detection of affected cortical areas over 1-2 cm is feasible by planar gamma camera, the smaller areas can be detected by SPECT.

99mTc-HM-PAO unit dose for leucocytes labelling

Detection of inflammatory processes (based on white blood cell migration) in case of
• Bacterial infection
• Abscess
• Inflammatory lesions of the intestine, bones or joints


• Myocardial perfusion scintigraphy for the detection and localisation of coronary artery disease (angina pectoris and myocardial infarction)
• Assessment of global ventricular function. First-pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for evaluation of left ventricular ejection fraction, volumes and regional wall motion.
• Scintimammography for the detection of suspected breast cancer when mammography is equivocal, inadequate or indeterminate.
• Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled to undergo initial surgery of the parathyroid glands.


Red Blood Cell Labelling

After radiolabelling with sodium (99mTc) pertechnetate solution, the solution obtained is indicated for
• Bone scintigraphy
• Cardiac scintigraphy, diagnosis of acute myocardial infarction After reconstitution with physiological sodium chloride solution in vivo or in vivo/in vitro red blood cell labelling for determination of blood volume and spleen scintigraphy.

Makro-Albumon (99mTc-MAA)

The labelled MAA is suitable for

  • Pulmonary perfusion scintigraphy
  • Pulmonary embolism and myocardial infarct
  • Chronic circulatory failure
  • Local respiratory distress
  • Emphysema
  • Tumour
  • Inflammation
  • Visualisation of venous circulation
  • Perfusion arterial scintigraphy of abdominal and retroperitoneal organs
  • Detection of deep vein thrombosis in the lower extremities and pelvis
  • Occlusion of the vena cava inferior

Leuco-Scint accessories kit

The kit contains sterile tubes and transfer pipettes for 3 complete leucocyte separations and labellings.

Methylene diphosphonic acid (MDP) 5.0 mg


  • Primary bone tumours imaging
  • Bone metastases (e.g. prostate, breast, lung cancer)
  • Osteomyelitis • metabolic bone disease
  • Paget’s disease
  • Fractures
  • Avascular necrosis
  • Loosened/inflamed arthricular prosthesis
  • Arthricular inflammations (rheumatoid arthritis)

MAG3 1 mg (Technetium (99mTc) tiatide)

After reconstitution and labelling with sodium (99mTc) pertechnetate solution, the diagnostic agent technetium (99mTc) tiatide may be used intravenously for the evaluation of nephrological and urological disorders in particular for the study of morphology, perfusion, and function of the kidney and characterisation of urinary outflow.


Isotopes For Diagnostic Imaging

Infection – Ga67

67Ga citrate: for scintigraphy in the diagnosis of malignant lymphomas, malignant melanoma, lung carcinomas, mesothelioma, hepatoma, head and neck tumours, sarcomas, miscellaneous malignancies and indications in inflammations and infections (sarcoidosis, tuberculosis, AIDS and miscellaneous infectious diseases).

Iodine 123

123I solution for injections: for non-invasive diagnostic investigations of thyroid abnormalities or dysfunction. 123I capsules: for non-invasive diagnostic investigations of thyroid abnormalities or dysfunction.

123I-[MIBG]: a diagnostic agent for the scintigraphic assessment of neuroendocrine tumours (such as neuroblastomas and pheochromocytoma), as well as for myocardial scintigraphy and functional imaging of malignant paragangliomas and carcinoid tumours.

Rhenium 186 (Re-186 Sulphide)

This medicinal product is indicated for use in adults in the treatment of inflammatory arthritis, such as rheumatoid poly-arthritis and haemophilic arthropathy, when there are inflammatory flare-ups in the shoulder, elbow, wrist, ankle or hip.

Sodium Iodide I-131

Sodium Iodide I 131 Solution Therapeutic is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine.

Isotopes For Radiosynovectomy

Yttrium 90 (Y-90) Citrate

Therapeutic irradiation of synovial hypertrophy of the knee joints (isotopic radiation synovectomy) mainly for mono- or oligo- arthritis of chronic inflammatory rheumatism particularly rheumatoid arthritis.

Quality Control

Quality Control Kits


The kit is a complete compilation of reagents to check the Tc-99m generator and the labelling work in the hot lab of the nuclear medicine department and gives rapid and reliable results.



DOTA-iPSMA (DOTA-hydrazinonicotinyl-Lys (NaI) -NH-CO-NH-Glu) 0.6mg

• Metastatic Castration Resistant Prostate Cancer


DOTA-TOC (DOTA-D-Phe1-Tyr3-Octreotide) 0.8 mg
• Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.